6YG Stock Chart & Stats
€30.40
-€0.60(-1.94%)
At close: 4:00 PM EDT
€30.40
-€0.60(-1.94%)
Day’s Range― - ―
52-Week Range€23.20 - €35.60
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€1.49B
Enterprise Value€1.19K
Total Cash (Recent Filing)€844.90M
Total Debt (Recent Filing)€435.68M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 06, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding50,865,574
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)4.59
Price to Sales (P/S)5.87
P/FCF Ratio-156.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€59.60Price Target Upside96.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.12
Revenue Forecast (FY)€391.86M
Bulls Say, Bears Say
Bulls Say
Commercial-stage Product & Proprietary ImmTAC PlatformImmunocore is a commercial-stage biotech with a marketed therapy (KIMMTRAK) and a proprietary TCR-based ImmTAC platform. Having a commercial product validates the business model, establishes recurring product revenue streams, and provides a foundation for durable growth and partner interest over the next several quarters.
Strong Revenue Scaling And High Gross ProfitabilityThe company shows sustained top-line growth with consistently very high gross margins, indicating strong unit economics. Durable revenue scaling and margin strength support reinvestment in R&D and commercial expansion and improve the path to sustainable profitability over a multi-quarter horizon.
Conservative Leverage And Financial FlexibilityRecent balance-sheet metrics show low leverage and sizable assets/equity, providing financial flexibility to support commercialization and pipeline investment. Conservative debt levels reduce refinancing risk and give management scope to fund milestones or pursue partnerships without immediate liquidity strain.
Bears Say
Ongoing Net Losses And Negative Operating ProfitabilityTrailing-twelve-month operating and net results remain loss-making even as losses narrow. Continued negative EBIT constrains the company’s ability to self-fund growth long term and increases reliance on external capital or partnerships, which can dilute equity or alter strategic timelines over coming quarters.
Negative And Volatile Operating Cash FlowOperating and free cash flow are currently negative and have shown volatility, creating forecasting risk for sustaining commercial and pipeline activities. Inconsistent cash generation heightens the need for financing or milestone payments and can pressure execution if external funding conditions tighten over the medium term.
Historical Leverage Volatility And Prior Higher Debt LoadAlthough leverage is conservative now, historical swings—including a materially higher debt position in 2024—indicate potential balance-sheet sensitivity. Such volatility implies that capital structure and funding needs can shift materially, raising execution and refinancing risk across multi-quarter planning horizons.
Immunocore Holdings News
6YG FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was €23.20 and its highest was €35.60 in the past 12 months.
What is Immunocore Holdings’s market cap?
Immunocore Holdings’s market cap is €1.49B.
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on May 06, 2026. The company reported €0.217 earnings per share for the quarter, beating the consensus estimate of -€0.205 by €0.422.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is <0.01.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 50,865,574 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of €0.217 in its last earnings report, beating expectations of -€0.205. Following the earnings report the stock price went up 6.612%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Currently, no hedge funds are holding shares in DE:6YG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€59.60 (96.04% Upside)
€59.60 (96.04% Upside)
Blogger Sentiment
Bullish
DE:6YG Sentiment 66%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.29%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
6YG Stock 12 Month Forecast
Average Price Target
€59.60
▲(96.04% Upside)